Centrum 7/6  banner

Moderna receives U.S. FDA approval for RSV vaccine mRESVIA

Moderna gets FDA approval for RSV vaccine mRESVIA

Moderna gets FDA approval for RSV vaccine mRESVIA

CAMBRIDGE, Mass. — Moderna announced Friday that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. The approval was granted under a breakthrough therapy designation and marks the second approved mRNA

PP_1170x120_10-25-21